Latest On Aldeyra Therapeutics, Inc (ALDX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-06 12:15 EST | News | Buy Aldeyra Therapeutics For Consecutive Runups | N/A |  |
| 2023-05-04 22:01 EST | News | Aldeyra Therapeutics GAAP EPS of -$0.27 beats by $0.02 | N/A | |
| 2023-04-12 00:18 EST | News | Aldeyra Therapeutics gains amid takeover speculation | N/A | |
| 2023-03-09 12:50 EST | News | Aldeyra Therapeutics GAAP EPS of -$1.06 beats by $0.10 | N/A | |
| 2023-03-09 12:49 EST | News | Aldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-02 12:50 EST | News | FDA accepts for priority review Aldeyra's ADX-2191 application in retinal cancer | N/A | |
| 2023-03-01 07:09 EST | News | Aldeyra Therapeutics: Catalyst Rich 2023 Holds Promise But Also Risk | N/A | |
| 2023-02-28 16:08 EST | News | Aldeyra gains on safety data for dry eye disease candidate | N/A | |
| 2023-02-07 16:03 EST | News | Aldeyra stock rises as dry eye disease drug gets FDA review | N/A | |
| 2022-12-21 17:39 EST | News | Aldeyra files for FDA approval of ADX‑2191 for rare eye cancer | N/A | |
| 2022-12-11 14:35 EST | News | Aldeyra Therapeutics: NDA Submission For Large Multi-Billion Dollar Market | N/A | |
| 2022-11-29 20:27 EST | News | Aldeyra Therapeutics seeks FDA approval of its treatment for dry eye disease symptoms | N/A | |
| 2022-11-11 05:51 EST | News | Aldeyra Therapeutics, Inc. (ALDX) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-10 12:39 EST | News | Aldeyra Therapeutics GAAP EPS of -$0.25 beats by $0.10 | N/A | |
| 2022-11-09 19:54 EST | News | Aldeyra Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-10-06 08:03 EST | News | Aldeyra stock rises as eye disorder drug ADX-2191 meets main goal in part 1 of phase 3 trial | N/A | |
| 2022-09-19 18:38 EST | News | Aldeyra Therapeutics: Dry Eye Is Just The Beginning For Novel MOA | N/A | |
| 2022-09-16 05:21 EST | News | Aldeyra Therapeutics (ALDX) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow | N/A | |
| 2022-09-14 18:07 EST | News | Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment | N/A | |
| 2022-08-05 14:22 EST | News | Aldeyra Therapeutics GAAP EPS of -$0.30 beats by $0.02 | N/A | |
| 2022-08-05 14:21 EST | News | Aldeyra Therapeutics stock rises 13% on Q2 beat with eyes on approval path for reproxalap | N/A | |
| 2022-08-05 14:21 EST | News | Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 07:32 EST | News | Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization | N/A | |
| 2022-07-12 22:36 EST | News | Aldeyra says trial for dry eye disease candidate reached key goals | N/A | |
| 2022-06-08 15:04 EST | News | Aldeyra stock soars as dry eye disease drug meets main goal in late stage study | N/A | |
| 2022-05-18 21:23 EST | News | Aldeyra says post-hoc analysis shows its eye therapy reduced ocular redness | N/A | |
| 2022-05-05 20:57 EST | News | Aldeyra Therapeutics GAAP EPS of -$0.29 beats by $0.04 | N/A | |
| 2022-05-05 20:56 EST | News | Aldeyra Therapeutics Inc. (ALDX) CEO Dr. Todd Brady on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-04 22:11 EST | News | Aldeyra Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-04-29 02:34 EST | News | Aldeyra Therapeutics CFO steps down, interim CFO appointed | N/A | |
| 2022-04-06 11:50 EST | News | Aldeyra Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-29 21:35 EST | News | Mid-stage trials show proof of concept for Aldeyra immune-mediated disease candidate | N/A | |
| 2022-03-18 11:16 EST | News | Aldeyra Therapeutics GAAP EPS of -$1.07 beats by $0.02 | N/A | |
| 2022-03-18 11:15 EST | News | Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-09 02:51 EST | News | Aldeyra Therapeutics starts phase 2 trial of ADX-2191 to treat rare eye disorders | N/A | |
| 2022-02-18 08:40 EST | News | Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts | N/A | |
| 2022-01-12 00:38 EST | News | Aldeyra reports positive top-line data from Phase 2 reproxalap study in dry eye disease | N/A | |
| 2022-01-05 00:54 EST | News | Aldeyra Therapeutics completes enrollment in part 1 of phase 3 study of eye disorder drug | N/A | |
| 2021-12-24 04:10 EST | News | Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap | N/A | |
| 2021-12-21 16:09 EST | News | Aldeyra defended at Citi despite setback to dry eye disease study for reproxalap | N/A | |
| 2021-12-20 21:54 EST | News | Aldeyra crashes on setback to dry eye disease study for reproxalap | N/A | |
| 2021-12-01 17:11 EST | News | Aldeyra Therapeutics (ALDX) Investor Presentation -Slideshow | N/A | |
| 2021-11-02 11:38 EST | News | Aldeyra Therapeutics posts results from mid-stage reproxalap dry eye disease trial | N/A | |
| 2021-10-28 16:20 EST | News | Aldeyra Therapeutics EPS misses by $0.01 | N/A | |
| 2021-10-28 16:19 EST | News | Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-09-30 08:46 EST | News | Revisiting Aldeyra Therapeutics | N/A | |
| 2021-09-21 11:29 EST | News | Aldeyra Therapeutics (ALDX) Investor Presentation - Slideshow | N/A | |
| 2021-08-05 21:31 EST | News | Aldeyra Therapeutics EPS misses by $0.03 | N/A | |
| 2021-08-05 21:28 EST | News | Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-04 23:14 EST | News | Aldeyra Therapeutics shares rise after FDA orphan drug status for ADX-2191 | N/A | |
About Aldeyra Therapeutics, Inc (ALDX):
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.
General
- Name Aldeyra Therapeutics, Inc
- Symbol ALDX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 11
- Fiscal Year EndDecember
- IPO Date2014-05-02
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.aldeyra.com
View More
Valuation
- Price/Book (Most Recent Quarter) 9.79
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.15
- Next Year EPS Estimate -$1.15
- Next Quarter EPS Estimate -$0.29
- Return on Assets -27%
- Return on Equity -70%
- Earnings Per Share -$2.00
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 548.54 million
- EBITDA -46566628
- Analyst Target Price $25
- Book Value Per Share $1.54
View More
Share Statistics
- Shares Outstanding 47.25 million
- Shares Float 37.94 million
- % Held by Insiders 228%
- % Held by Institutions 67.35%
- Shares Short 1.8 million
- Shares Short Prior Month 1.73 million
- Short Ratio 1.68
- Short % of Float 4%
- Short % of Shares Outstanding 4%
View More
Technicals
- Beta 1.62
- 52 Week High $14.62
- 52 Week Low $1.81
- 50 Day Moving Average 11.98
- 200 Day Moving Average 8.67
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Aldeyra Therapeutics, Inc (ALDX) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Aldeyra Therapeutics, Inc (ALDX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-11 | $N/A | -$0.30 | -$0.30 | 0.43% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.23 | -$0.27 | 15.53% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.25 | -$0.35 | 27.91% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.34 | -$0.46 | 26.8% |
| 2019-12-31 | 2020-03-12 | $N/A | -$0.48 | -$0.70 | 31.1% |
| 2019-09-30 | 2019-11-07 | $N/A | -$0.69 | -$0.56 | -23.68% |
| 2019-06-30 | 2019-08-08 | $N/A | -$0.49 | -$0.49 | -0.64% |
| 2019-03-31 | 2019-05-09 | $N/A | -$0.58 | -$0.44 | -32.33% |
| 2018-12-31 | 2019-03-08 | $N/A | -$0.39 | -$0.43 | 9.07% |
| 2018-09-30 | 2018-11-14 | $N/A | -$0.52 | -$0.48 | -9.47% |
| 2018-06-30 | 2018-08-09 | $N/A | -$0.46 | -$0.43 | -8.24% |
| 2018-03-31 | 2018-05-15 | $N/A | -$0.43 | -$0.38 | -14.15% |
| 2017-12-31 | 2018-03-29 | $N/A | -$0.36 | -$0.32 | -13.39% |
| 2017-09-30 | 2017-11-09 | $N/A | -$0.32 | -$0.35 | 9.22% |
| 2017-06-30 | 2017-08-07 | $N/A | -$0.35 | -$0.37 | 5.41% |
| 2017-03-31 | 2017-05-15 | $N/A | -$0.37 | -$0.35 | -7.25% |
| 2016-12-31 | 2017-03-30 | $N/A | -$0.35 | -$0.46 | 23.08% |
| 2016-09-30 | 2016-11-14 | $N/A | -$0.38 | -$0.41 | 7.32% |
| 2016-06-30 | 2016-08-10 | $N/A | -$0.41 | -$0.44 | 7.24% |
| 2016-03-31 | 2016-05-09 | $N/A | -$0.51 | -$0.50 | -2.51% |
| 2015-12-31 | 2016-03-30 | $N/A | -$0.46 | -$0.37 | -24.32% |
| 2015-09-30 | 2015-11-12 | $N/A | -$0.35 | -$0.30 | -16.67% |
| 2015-06-30 | 2015-08-11 | $N/A | -$0.27 | -$0.35 | 22.86% |
| 2015-03-31 | 2015-05-13 | $N/A | -$0.32 | -$0.38 | 15.79% |
| 2014-12-31 | 2015-03-19 | $N/A | -$0.30 | -$0.40 | 25% |
| 2014-09-30 | 2014-11-10 | $N/A | -$0.36 | -$0.32 | -12.5% |
| 2014-06-30 | 2014-08-04 | $N/A | -$1.56 | -$0.53 | -194.34% |
| 2014-03-31 | 2014-05-28 | $N/A | -$0.18 |
Aldeyra Therapeutics, Inc (ALDX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Aldeyra Therapeutics, Inc (ALDX) Chart:
Aldeyra Therapeutics, Inc (ALDX) News:
Below you will find a list of latest news for Aldeyra Therapeutics, Inc (ALDX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Aldeyra Therapeutics, Inc (ALDX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-10-17 | 2.5 | 2.9 | CALL | 0 | 1 | 0 | TRUE | 0 | 0 |
| 2025-10-17 | 4 | 0 | CALL | 0 | 0 | 88.32 | TRUE | 0 | 0 |
| 2025-10-17 | 5 | 0.65 | CALL | 19 | 309 | 69.94 | TRUE | 0.25 | 0.63 |
| 2025-10-17 | 6 | 0.1 | CALL | 1 | 30 | 45.57 | FALSE | 0.1 | 0 |
| 2025-10-17 | 7.5 | 0.05 | CALL | 0 | 31 | 158.64 | FALSE | 0 | 0 |
| 2025-10-17 | 9 | 0 | CALL | 0 | 0 | 366.71 | FALSE | 0 | 0 |
| 2025-10-17 | 10 | 0.05 | CALL | 0 | 1 | 176.46 | FALSE | 0 | 0 |
| 2025-10-17 | 2.5 | 0 | PUT | 0 | 0 | 719.3 | FALSE | 0 | 0 |
| 2025-10-17 | 4 | 0 | PUT | 0 | 0 | 195.25 | FALSE | 0 | 0 |
| 2025-10-17 | 5 | 0.15 | PUT | 0 | 383 | 135.14 | FALSE | 0 | 0 |
| 2025-10-17 | 6 | 0 | PUT | 0 | 0 | 116.62 | TRUE | 0 | 0 |
| 2025-10-17 | 7.5 | 0 | PUT | 0 | 0 | 187.09 | TRUE | 0 | 0 |
| 2025-10-17 | 9 | 0 | PUT | 0 | 0 | 149.89 | TRUE | 0 | 0 |
| 2025-10-17 | 10 | 0 | PUT | 0 | 0 | 175.92 | TRUE | 0 | 0 |
| 2025-11-21 | 1 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-11-21 | 2 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-11-21 | 3 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-11-21 | 4 | 0 | CALL | 0 | 0 | 111.25 | TRUE | 0 | 0 |
| 2025-11-21 | 5 | 0.7 | CALL | 0 | 40 | 105.23 | TRUE | 0 | 0 |
| 2025-11-21 | 6 | 0.25 | CALL | 0 | 9 | 95.97 | FALSE | 0 | 0 |
| 2025-11-21 | 7 | 0.05 | CALL | 0 | 1 | 76.35 | FALSE | 0 | 0 |
| 2025-11-21 | 8 | 0.05 | CALL | 0 | 20 | 62.17 | FALSE | 0 | 0 |
| 2025-11-21 | 9 | 0 | CALL | 0 | 0 | 190.11 | FALSE | 0 | 0 |
| 2025-11-21 | 10 | 0 | CALL | 0 | 0 | 208.69 | FALSE | 0 | 0 |
| 2025-11-21 | 1 | 0 | PUT | 0 | 0 | 871.95 | FALSE | 0 | 0 |
| 2025-11-21 | 2 | 0 | PUT | 0 | 0 | 461.69 | FALSE | 0 | 0 |
| 2025-11-21 | 3 | 0 | PUT | 0 | 0 | 311.37 | FALSE | 0 | 0 |
| 2025-11-21 | 4 | 0.24 | PUT | 0 | 50 | 124.37 | FALSE | 0 | 0 |
| 2025-11-21 | 5 | 0.4 | PUT | 0 | 62 | 114.52 | FALSE | 0 | 0 |
| 2025-11-21 | 6 | 0 | PUT | 0 | 0 | 98.37 | TRUE | 0 | 0 |
| 2025-11-21 | 7 | 0 | PUT | 0 | 0 | 105.76 | TRUE | 0 | 0 |
| 2025-11-21 | 8 | 0 | PUT | 0 | 0 | 78.75 | TRUE | 0 | 0 |
| 2025-11-21 | 9 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-11-21 | 10 | 0 | PUT | 0 | 0 | 98.32 | TRUE | 0 | 0 |
| 2025-12-19 | 2.5 | 3.46 | CALL | 1 | 49 | 170.15 | TRUE | 3.46 | 0 |
| 2025-12-19 | 4 | 1.62 | CALL | 0 | 23 | 176.19 | TRUE | 0 | 0 |
| 2025-12-19 | 5 | 1.35 | CALL | 0 | 920 | 129.92 | TRUE | 0 | 0 |
| 2025-12-19 | 6 | 0.7 | CALL | 10 | 24 | 75.56 | FALSE | 0.7 | 0 |
| 2025-12-19 | 7.5 | 0.68 | CALL | 17 | 2884 | 115.64 | FALSE | 0.18 | 0.36 |
| 2025-12-19 | 9 | 0 | CALL | 0 | 0 | 145.59 | FALSE | 0 | 0 |
| 2025-12-19 | 10 | 0.18 | CALL | 25 | 640 | 98.33 | FALSE | 0.02 | 0.13 |
| 2025-12-19 | 2.5 | 0.25 | PUT | 0 | 2005 | 202.93 | FALSE | 0 | 0 |
| 2025-12-19 | 4 | 0.7 | PUT | 0 | 3 | 179.33 | FALSE | 0 | 0 |
| 2025-12-19 | 5 | 1 | PUT | 0 | 1170 | 152.76 | FALSE | 0 | 0 |
| 2025-12-19 | 6 | 1.75 | PUT | 0 | 2 | 157.36 | TRUE | 0 | 0 |
| 2025-12-19 | 7.5 | 2.5 | PUT | 1 | 5 | 126.84 | TRUE | 2.5 | 0 |
| 2025-12-19 | 9 | 0 | PUT | 0 | 0 | 91.44 | TRUE | 0 | 0 |
| 2025-12-19 | 10 | 4.55 | PUT | 0 | 1 | 115.47 | TRUE | 0 | 0 |
| 2026-01-16 | 2.5 | 3.1 | CALL | 0 | 1631 | 141.74 | TRUE | 0 | 0 |
| 2026-01-16 | 4 | 0 | CALL | 0 | 0 | 128.97 | TRUE | 0 | 0 |
| 2026-01-16 | 5 | 1.7 | CALL | 75 | 5297 | 112.82 | TRUE | 0.3 | 0.21 |
| 2026-01-16 | 6 | 1 | CALL | 0 | 38 | 139.5 | FALSE | 0 | 0 |
| 2026-01-16 | 7.5 | 0.6 | CALL | 0 | 3308 | 112.59 | FALSE | 0 | 0 |
| 2026-01-16 | 9 | 0 | CALL | 0 | 0 | 136.89 | FALSE | 0 | 0 |
| 2026-01-16 | 10 | 0.4 | CALL | 0 | 3097 | 103.62 | FALSE | 0 | 0 |
| 2026-01-16 | 12.5 | 0.22 | CALL | 0 | 844 | 123.64 | FALSE | 0 | 0 |
| 2026-01-16 | 2.5 | 0.3 | PUT | 0 | 508 | 189.21 | FALSE | 0 | 0 |
| 2026-01-16 | 4 | 0.8 | PUT | 0 | 47 | 165.7 | FALSE | 0 | 0 |
| 2026-01-16 | 5 | 0.95 | PUT | 0 | 229 | 128.81 | FALSE | 0 | 0 |
| 2026-01-16 | 6 | 0 | PUT | 0 | 0 | 148.25 | TRUE | 0 | 0 |
| 2026-01-16 | 7.5 | 2.45 | PUT | 0 | 24 | 117.7 | TRUE | 0 | 0 |
| 2026-01-16 | 9 | 0 | PUT | 0 | 0 | 112.65 | TRUE | 0 | 0 |
| 2026-01-16 | 10 | 5 | PUT | 0 | 24 | 111.05 | TRUE | 0 | 0 |
| 2026-01-16 | 12.5 | 6.8 | PUT | 0 | 3 | 103.38 | TRUE | 0 | 0 |
| 2026-03-20 | 2.5 | 3.3 | CALL | 4 | 27 | 63.69 | TRUE | 3.3 | 0 |
| 2026-03-20 | 4 | 0 | CALL | 0 | 0 | 107.46 | TRUE | 0 | 0 |
| 2026-03-20 | 5 | 1.86 | CALL | 2 | 41 | 99.9 | TRUE | 0.46 | 0.33 |
| 2026-03-20 | 6 | 1.25 | CALL | 0 | 2 | 122.91 | FALSE | 0 | 0 |
| 2026-03-20 | 7.5 | 0.6 | CALL | 0 | 141 | 101.02 | FALSE | 0 | 0 |
| 2026-03-20 | 9 | 0 | CALL | 0 | 0 | 92.12 | FALSE | 0 | 0 |
| 2026-03-20 | 10 | 0.6 | CALL | 0 | 317 | 96.61 | FALSE | 0 | 0 |
| 2026-03-20 | 2.5 | 0.3 | PUT | 0 | 195 | 158.07 | FALSE | 0 | 0 |
| 2026-03-20 | 4 | 0.8 | PUT | 0 | 50 | 141.3 | FALSE | 0 | 0 |
| 2026-03-20 | 5 | 1.25 | PUT | 0 | 5 | 135.57 | FALSE | 0 | 0 |
| 2026-03-20 | 6 | 1.95 | PUT | 0 | 4 | 108.25 | TRUE | 0 | 0 |
| 2026-03-20 | 7.5 | 0 | PUT | 0 | 0 | 104.52 | TRUE | 0 | 0 |
| 2026-03-20 | 9 | 0 | PUT | 0 | 0 | 94.93 | TRUE | 0 | 0 |
| 2026-03-20 | 10 | 0 | PUT | 0 | 0 | 98.23 | TRUE | 0 | 0 |
Latest ALDX Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 100 | $3.345 |
| Jun 13, 2022 7:59 PM EST | 170 | $3.345 |
| Jun 13, 2022 7:59 PM EST | 10 | $3.345 |
| Jun 13, 2022 7:59 PM EST | 100 | $3.345 |
| Jun 13, 2022 7:59 PM EST | 30 | $3.345 |
Aldeyra Therapeutics, Inc (ALDX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520167714/0001193125-20-167714-index.htm |
| 2018-07-26 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1341235/000000000018022951/0000000000-18-022951-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000031506619000826/0000315066-19-000826-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000031506620000826/0000315066-20-000826-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000083423720008145/0000834237-20-008145-index.htm |
| 2020-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000083423720010003/0000834237-20-010003-index.htm |
| 2018-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924318015766/0000899243-18-015766-index.htm |
| 2018-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924318015767/0000899243-18-015767-index.htm |
| 2018-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924318015769/0000899243-18-015769-index.htm |
| 2018-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924318015770/0000899243-18-015770-index.htm |
| 2018-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924318015771/0000899243-18-015771-index.htm |
| 2018-08-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924318020972/0000899243-18-020972-index.htm |
| 2018-08-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924318020978/0000899243-18-020978-index.htm |
| 2018-08-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924318020988/0000899243-18-020988-index.htm |
| 2019-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319006729/0000899243-19-006729-index.htm |
| 2019-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319006730/0000899243-19-006730-index.htm |
| 2019-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319006732/0000899243-19-006732-index.htm |
| 2019-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319006734/0000899243-19-006734-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319015819/0000899243-19-015819-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319015820/0000899243-19-015820-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319015821/0000899243-19-015821-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319015822/0000899243-19-015822-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319015824/0000899243-19-015824-index.htm |
| 2019-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023128/0000899243-19-023128-index.htm |
| 2019-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023129/0000899243-19-023129-index.htm |
| 2019-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023265/0000899243-19-023265-index.htm |
| 2019-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023315/0000899243-19-023315-index.htm |
| 2019-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023317/0000899243-19-023317-index.htm |
| 2019-09-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023539/0000899243-19-023539-index.htm |
| 2019-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023628/0000899243-19-023628-index.htm |
| 2019-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023718/0000899243-19-023718-index.htm |
| 2019-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023719/0000899243-19-023719-index.htm |
| 2019-09-17 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023735/0000899243-19-023735-index.htm |
| 2019-09-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023923/0000899243-19-023923-index.htm |
| 2019-09-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023982/0000899243-19-023982-index.htm |
| 2019-09-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319024225/0000899243-19-024225-index.htm |
| 2019-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319024582/0000899243-19-024582-index.htm |
| 2019-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924319029509/0000899243-19-029509-index.htm |
| 2020-01-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320001258/0000899243-20-001258-index.htm |
| 2020-01-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320001261/0000899243-20-001261-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320007060/0000899243-20-007060-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320007064/0000899243-20-007064-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320007067/0000899243-20-007067-index.htm |
| 2020-03-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320007447/0000899243-20-007447-index.htm |
| 2020-03-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320007448/0000899243-20-007448-index.htm |
| 2020-03-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320008616/0000899243-20-008616-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320016177/0000899243-20-016177-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320016180/0000899243-20-016180-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320016181/0000899243-20-016181-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320016182/0000899243-20-016182-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320016183/0000899243-20-016183-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320016185/0000899243-20-016185-index.htm |
| 2020-07-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000089924320019004/0000899243-20-019004-index.htm |
| 2019-09-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000090266419003845/0000902664-19-003845-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000090266420000962/0000902664-20-000962-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000090445418000424/0000904454-18-000424-index.htm |
| 2019-01-22 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000090445419000069/0000904454-19-000069-index.htm |
| 2019-03-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000090445419000337/0000904454-19-000337-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000090445419000466/0000904454-19-000466-index.htm |
| 2020-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000090445420000020/0000904454-20-000020-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1341235/000090445420000398/0000904454-20-000398-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000101359419000164/0001013594-19-000164-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000101359420000132/0001013594-20-000132-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000117891319000432/0001178913-19-000432-index.htm |
| 2018-06-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518188147/0001193125-18-188147-index.htm |
| 2018-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518203119/0001193125-18-203119-index.htm |
| 2018-07-20 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1341235/000119312518222562/0001193125-18-222562-index.htm |
| 2018-07-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1341235/000119312518225751/0001193125-18-225751-index.htm |
| 2018-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518232408/0001193125-18-232408-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518243481/0001193125-18-243481-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1341235/000119312518244346/0001193125-18-244346-index.htm |
| 2018-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518281789/0001193125-18-281789-index.htm |
| 2018-09-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518283160/0001193125-18-283160-index.htm |
| 2018-09-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1341235/000119312518283947/0001193125-18-283947-index.htm |
| 2018-09-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1341235/000119312518287518/0001193125-18-287518-index.htm |
| 2018-09-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518287591/0001193125-18-287591-index.htm |
| 2018-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518326140/0001193125-18-326140-index.htm |
| 2018-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1341235/000119312518326837/0001193125-18-326837-index.htm |
| 2018-11-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518331873/0001193125-18-331873-index.htm |
| 2018-12-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312518360931/0001193125-18-360931-index.htm |
| 2018-12-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1341235/000119312518360963/0001193125-18-360963-index.htm |
| 2019-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519019770/0001193125-19-019770-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000119312519040933/0001193125-19-040933-index.htm |
| 2019-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519055552/0001193125-19-055552-index.htm |
| 2019-03-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519067948/0001193125-19-067948-index.htm |
| 2019-03-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1341235/000119312519069189/0001193125-19-069189-index.htm |
| 2019-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519085920/0001193125-19-085920-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519142173/0001193125-19-142173-index.htm |
| 2019-06-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519166628/0001193125-19-166628-index.htm |
| 2019-06-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519180730/0001193125-19-180730-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519216016/0001193125-19-216016-index.htm |
| 2019-09-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519235793/0001193125-19-235793-index.htm |
| 2019-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519252836/0001193125-19-252836-index.htm |
| 2019-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519279627/0001193125-19-279627-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519286617/0001193125-19-286617-index.htm |
| 2019-12-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312519304808/0001193125-19-304808-index.htm |
| 2020-01-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520006782/0001193125-20-006782-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000119312520038085/0001193125-20-038085-index.htm |
| 2020-02-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520045535/0001193125-20-045535-index.htm |
| 2020-02-25 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000119312520047397/0001193125-20-047397-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520070920/0001193125-20-070920-index.htm |
| 2020-03-12 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1341235/000119312520071672/0001193125-20-071672-index.htm |
| 2020-04-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520105860/0001193125-20-105860-index.htm |
| 2020-05-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520131009/0001193125-20-131009-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520135600/0001193125-20-135600-index.htm |
| 2020-05-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520146738/0001193125-20-146738-index.htm |
| 2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520160151/0001193125-20-160151-index.htm |
| 2020-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520167714/0001193125-20-167714-index.htm |
| 2020-07-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520188425/0001193125-20-188425-index.htm |
| 2020-07-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1341235/000119312520191905/0001193125-20-191905-index.htm |
| 2020-07-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520192321/0001193125-20-192321-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520211319/0001193125-20-211319-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1341235/000119312520286220/0001193125-20-286220-index.htm |
| 2019-03-08 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1341235/000156459019006997/0001564590-19-006997-index.htm |
| 2019-04-22 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1341235/000156459019012248/0001564590-19-012248-index.htm |
| 2019-04-22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1341235/000156459019012254/0001564590-19-012254-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1341235/000156459019018542/0001564590-19-018542-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1341235/000156459019031031/0001564590-19-031031-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1341235/000156459019041846/0001564590-19-041846-index.htm |
| 2020-03-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1341235/000156459020010493/0001564590-20-010493-index.htm |
| 2020-04-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1341235/000156459020018862/0001564590-20-018862-index.htm |
| 2020-04-27 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1341235/000156459020018879/0001564590-20-018879-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1341235/000156459020022912/0001564590-20-022912-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1341235/000156459020037714/0001564590-20-037714-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1341235/000156459020051290/0001564590-20-051290-index.htm |
| 2019-02-11 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1341235/000158274619000001/0001582746-19-000001-index.htm |
| 2018-07-27 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1341235/999999999518001924/9999999995-18-001924-index.htm |
| 2018-10-04 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1341235/999999999718008382/9999999997-18-008382-index.htm |
Aldeyra Therapeutics, Inc (ALDX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aldeyra Therapeutics, Inc (ALDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 228%Institutional Ownership: 6735%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-03-05 | David J Clark | Chief Medical Officer | Buy | 3,503.00 | 11,512.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319006730/0000899243-19-006730-index.htm | ||
| 2020-03-16 | RICHARD DOUGLAS | Director | Buy | 40,000.00 | 2.75 | 110,000.00 | 125,000.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924320008616/0000899243-20-008616-index.htm |
| 2019-09-06 | David J Clark | Chief Medical Officer | Buy | 5,000.00 | 5.06 | 25,311.00 | 17,878.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023265/0000899243-19-023265-index.htm |
| 2019-09-17 | Ben Bronstein | Director | Buy | 1,700.00 | 5.85 | 9,945.00 | 18,644.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023923/0000899243-19-023923-index.htm |
| 2019-03-26 | JESSE I TREU | Director | Sell | 96,298.00 | 10.01 | 963,942.98 | 1,877,091.00 | https://www.sec.gov/Archives/edgar/data/1341235/000090445419000337/0000904454-19-000337-index.htm |
| 2019-09-12 | MARTIN JOSEPH JOYCE | Director | Buy | 1,700.00 | 5.86 | 9,964.21 | 19,644.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023628/0000899243-19-023628-index.htm |
| 2020-03-02 | David McMullin | Chief Commercial Officer | Buy | 250,000.00 | 257,703.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924320007064/0000899243-20-007064-index.htm | ||
| 2020-03-02 | Joshua Reed | Chief Financial Officer | Buy | 250,000.00 | 285,774.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924320007067/0000899243-20-007067-index.htm | ||
| 2019-03-05 | Joshua Reed | Chief Financial Officer | Buy | 29,637.00 | 29,637.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319006732/0000899243-19-006732-index.htm | ||
| 2019-09-05 | Joshua Reed | Chief Financial Officer | Buy | 3,200.00 | 4.71 | 15,072.00 | 35,774.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023129/0000899243-19-023129-index.htm |
| 2019-09-09 | RICHARD DOUGLAS | Director | Buy | 10,000.00 | 4.91 | 49,106.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023315/0000899243-19-023315-index.htm |
| 2019-03-05 | Todd C Brady | President and CEO | Buy | 250,000.00 | 556,054.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319006729/0000899243-19-006729-index.htm | ||
| 2019-09-09 | Todd C Brady | President and CEO | Buy | 10,000.00 | 4.89 | 48,887.00 | 568,991.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023317/0000899243-19-023317-index.htm |
| 2019-09-10 | Todd C Brady | President and CEO | Buy | 10,000.00 | 5.39 | 53,937.00 | 578,991.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023317/0000899243-19-023317-index.htm |
| 2019-09-13 | Todd C Brady | President and CEO | Buy | 10,000.00 | 5.79 | 57,900.00 | 588,991.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023718/0000899243-19-023718-index.htm |
| 2019-09-16 | Todd C Brady | President and CEO | Buy | 3,000.00 | 6.03 | 18,090.00 | 591,991.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023718/0000899243-19-023718-index.htm |
| 2019-09-10 | RICHARD DOUGLAS | Director | Buy | 10,000.00 | 5.09 | 50,857.00 | 60,000.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023315/0000899243-19-023315-index.htm |
| 2019-09-05 | David McMullin | Chief Commerical Officer | Buy | 4,329.00 | 4.68 | 20,259.72 | 6,148.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023128/0000899243-19-023128-index.htm |
| 2019-09-18 | Todd C Brady | President and CEO | Buy | 14,288.00 | 5.91 | 84,464.94 | 614,826.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023982/0000899243-19-023982-index.htm |
| 2019-09-23 | Todd C Brady | President and CEO | Buy | 8,680.00 | 5.81 | 50,432.54 | 623,506.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319024225/0000899243-19-024225-index.htm |
| 2020-07-09 | PERCEPTIVE ADVISORS LLC | 10% Share Holder | Buy | 3,200,000.00 | 4.25 | 13,600,000.00 | 6,285,458.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924320019004/0000899243-20-019004-index.htm |
| 2019-09-30 | Todd C Brady | President and CEO | Buy | 8,710.00 | 5.68 | 49,483.25 | 632,216.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319024582/0000899243-19-024582-index.htm |
| 2019-12-16 | Todd C Brady | President and CEO | Buy | 20,000.00 | 5.10 | 101,908.00 | 652,216.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319029509/0000899243-19-029509-index.htm |
| 2019-09-11 | RICHARD DOUGLAS | Director | Buy | 10,000.00 | 5.75 | 57,529.00 | 70,000.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023539/0000899243-19-023539-index.htm |
| 2019-09-12 | RICHARD DOUGLAS | Director | Buy | 10,000.00 | 6.03 | 60,276.00 | 80,000.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023539/0000899243-19-023539-index.htm |
| 2019-09-13 | RICHARD DOUGLAS | Director | Buy | 5,000.00 | 6.00 | 30,000.00 | 85,000.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924319023719/0000899243-19-023719-index.htm |
| 2019-03-26 | JESSE I TREU | Director | Sell | 445.00 | 10.01 | 4,454.45 | 8,763.00 | https://www.sec.gov/Archives/edgar/data/1341235/000090445419000337/0000904454-19-000337-index.htm |
| 2020-03-02 | Todd C Brady | President and CEO | Buy | 250,000.00 | 902,216.00 | https://www.sec.gov/Archives/edgar/data/1341235/000089924320007060/0000899243-20-007060-index.htm |